CASP3 and Hepatic failure: In vivo and in vitro experiments demonstrated that two new GSDME-derived inhibitors, Ac-DMPD-CMK and Ac-DMLD-CMK, could directly bind to the catalytic domains of caspase-3 and specifically limit caspase-3 activity, and effectively prevent caspase-3/GSDME-dependent hepatocyte pyroptosis and the resulting liver failure [86].